Breast cancer expresses functional NMDA receptors William G. NorthGuohong GaoLauna Lynch Preclinical study 26 September 2009 Pages: 307 - 314
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer Karin RennstamNicole McMichaelIngrid Hedenfalk Preclinical study 01 October 2009 Pages: 315 - 324
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer Michael S. SabelGang SuAlfred E. Chang Preclinical study 03 October 2009 Pages: 325 - 336
RETRACTED ARTICLE: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors Aamir AhmadZhiwei WangFazlul H. Sarkar Preclinical study 08 October 2009 Pages: 337 - 346
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome Lyndsay M. MurrowSireesha V. GarimellaStanley Lipkowitz Preclinical study 10 October 2009 Pages: 347 - 357
IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo Esther ChaLaura GrahamHarry D. Bear Preclinical study 14 October 2009 Pages: 359 - 369
Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody H. J. HnatyszynM. LiuM. E. Lippman Preclinical study 20 October 2009 Pages: 371 - 380
A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions Matthew H. HerynkTorsten HoppSuzanne A. W. Fuqua Preclinical study 20 October 2009 Pages: 381 - 393
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance Hitomi ImachiKoji MuraoAkira Yamauchi Preclinical study 22 October 2009 Pages: 395 - 407
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes Gabriel N. HortobagyiHenry L. GomezHenri H. Roché Clinical trial 08 May 2010 Pages: 409 - 418
Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer Vicky S. SabineAndrew H. SimsJohn M. S. Bartlett Clinical trial 18 May 2010 Pages: 419 - 428
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients Jean-Yves PiergaSuzette DelalogeMichel Marty Clinical trial 18 May 2010 Pages: 429 - 437
New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study Pierre Ludovic GiacaloneGauthier RathatCaroline Rouleau Clinical Trial 26 May 2010 Pages: 439 - 451
Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: a comparison of 99mTc-tin colloid and 99mTc-phytate efficiency Ju Won SeokYoo Shin ChoiSung Jun Park Clinical trial 09 June 2010 Pages: 453 - 457
Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis Theodoros N. SergentanisKonstantinos P. Economopoulos Epidemiology 25 December 2009 Pages: 459 - 469
Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis Yun ChenJianping Pei Epidemiology 31 December 2009 Pages: 471 - 481
Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects Ke-Da YuGen-Hong DiZhi-Ming Shao Epidemiology 31 December 2009 Pages: 483 - 488
XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis Li-Xin QiuChen MaoXi-Chun Hu Epidemiology 05 January 2010 Pages: 489 - 493
Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls Xiangyu MaXiaowei QiJun Jiang Epidemiology 06 January 2010 Pages: 495 - 501
Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects Lei YaoXiaoJia YuLong Yu Epidemiology 06 January 2010 Pages: 503 - 507
No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: a meta-analysis based on 9,710 cases and 11,041 controls Xiangyu MaChunhai ChenBin Xu Epidemiology 06 January 2010 Pages: 509 - 514
Breast cancer survival in women of African descent living in the US and in the Caribbean: effect of place of birth Emanuela TaioliAllison Attong-RogersCamille Ragin Epidemiology 06 January 2010 Pages: 515 - 520
Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects Li-Xin QiuLei YaoXi-Chun Hu Epidemiology 07 January 2010 Pages: 521 - 525
Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case–control studies Dongying GuMeilin WangJinfei Chen Epidemiology 07 January 2010 Pages: 527 - 531
Temporal trends in area socioeconomic disparities in breast-cancer incidence and mortality, 1988–2005 Mario SchootmanMin LianDonna B. Jeffe Epidemiology 07 January 2010 Pages: 533 - 543
Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis Konstantinos P. EconomopoulosTheodoros N. Sergentanis Epidemiology 07 January 2010 Pages: 545 - 551
Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer Jenny Chia-Yun WuMatti HakamaHsiu-Hsi Chen Epidemiology 07 January 2010 Pages: 553 - 566
Two founder BRCA2 mutations predispose to breast cancer in young women Mar InfanteMercedes DuránEladio A. Velasco Brief Report 01 December 2009 Pages: 567 - 571
Evaluation of screening instruments for depression and anxiety in breast cancer survivors Susanna AlexanderClare PalmerPatrick C. Stone Brief Report 04 December 2009 Pages: 573 - 578
Orally administered Endoxifen is a new therapeutic agent for breast cancer Ateeq AhmadShoukath M. AliImran Ahmad Brief Report 06 January 2010 Pages: 579 - 584
Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy Anne H. BlaesPhilippe GaillardBeth Virnig Brief Report 08 January 2010 Pages: 585 - 590
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register Javier PuenteSara López-TarruellaMiguel Martin Brief Report 10 January 2010 Pages: 591 - 600
Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence Miguel MuñozMarisa RossoRafael Coveñas Letter to the Editor 24 March 2010 Pages: 601 - 603
High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients Ava KwongE. K. O. NgE. S. K. Ma Letter to the Editor 16 April 2010 Pages: 605 - 607
